Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration Award
Forecast
National Institutes of Health plans to offer grants to the applicants described in the notice. It is a forecast: the notice is expected around September 1, 2026, with applications due around February 16, 2027.
From the official notice on Grants.gov, last changed July 20, 2026. Checked October 31, 2026.
- Award ceilingnot stated
- Award floornot stated
- Expected awardsnot stated
- Total fundingnot stated
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Forecast posted | July 20, 2026 |
|---|---|
| Expected posting | September 1, 2026 |
| Expected deadline | February 16, 2027 |
| Expected award date | December 15, 2027 |
Add the deadline to your calendar
Who can apply
This opportunity is open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligibility for this NOFO is limited to recipients that have successfully competed for an award under the Clinical and Translational Science Awards (CTSA) UM1 NOFO PAR-24-272 or subsequent iterations, as either a prime recipient or as a partnering institution.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The purpose of the Congressionally mandated Clinical and Translational Science Award (CTSA) Program is to accelerate the translation of scientific discoveries into treatments, diagnostics, and health interventions that improve patient and public health by funding and coordinating a national network of academic medical centers that provide the infrastructure, expertise, training, and collaboration needed to move discoveries from the laboratory into clinical practice and community health. The purpose of the reissuance of the Collaborative and Innovative Acceleration Award for the CTSA Program Notice of Funding Opportunity (NOFO) is to support the collaborative development of innovative approaches, technologies, or models that synergistically enhance the impact of research, advance translational science, and bring more treatments for all people more quickly. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. This is a Forecast for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to Division of Clinical Innovation, NCATS, ctsa_collaborativeinnovation@mail.nih.gov, Please contact via e-mail..
Questions people ask
Who can apply for Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration Award?
National Institutes of Health accepts applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration Award?
Expected deadline February 16, 2027. Confirm the date and time in the official notice on Grants.gov.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience